Skip to main content

Table 3 Distribution of indication for oral anticoagulation (OAC) and corresponding time in therapeutic range in regular medical care and coagulation service

From: Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL

Indication for OAC Regular medical care Coagulation service
Frequency Time in therapeutic range Frequency Time in therapeutic range
Atrial fibrillation 66.2% (1,332) 67.5% (49.3/83.3) 61.1% (464) 75.0% (61.8/77.3)
Deep vein thrombosis 6.1% (123) 65.2% (46.8/75.3) 14.2% (108) 75.3% (66.1/85.0)
Peripheral vascular bypass surgery 8.0% (160) 64.9% (47.1/81.2) 2.2% (17) 74.9% (61.8/77.3)
Prosthetic heart valve 9.7% (195) 42.2% (30.4/68.3) 7.4% (56) 76.8% (63.0/82.8)
Pulmonary embolism 7.7% (154) 66.5% (50.6/82.6) 13.3% (101) 75.5% (64.7/84.7)
Others* 5.0% (100) 70.1% (54.3/82.1) 5.0% (38) 79.2% (59.8/88.0)
  1. Patients can have more than one indication for oral anticoagulation (OAC) with vitamin K antagonist; indication is described in 2,011 of patients in regular medical care and 760 patients in the coagulation service cohort. In coagulation service patients with pre-treatment in regular medical care, information on regular medical care pre-treatment are described within regular medical care cohort (non-disjunct data). Frequency of indication is depicted as relative and absolute frequency. Time in therapeutic range was calculated in patients with at least 4 months of anticoagulation treatment except self-management patients (1,160 patients in regular medical care and 560 patients in coagulation service, respectively). *e.g., cerebral venous sinus thrombosis, Paget-Schrötter disease.